DAIC

JULY 11, 2024

a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Medical device company R3 Vascular Inc., Image courtesy: R3 Vascular Inc.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Stents Stent Education 105

DAIC

MAY 30, 2024

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. .

Stents 105

Stents Stent Peripheral Arterial Disease Cardiovascular Disease 105

DAIC

JUNE 18, 2024

FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.

Coronary Artery Disease 105

Coronary Artery Disease Stents Stent Technology 105

DAIC

FEBRUARY 14, 2024

Encouraged by the early clinical results, Efemoral Medical is now developing an additional device for treating below-the-knee (infrapopliteal) arteries in patients with CLTI. Diseased human arteries are most simply, reliably, and successfully treated with drug-eluting, balloon-expandable stents," said Lewis B.

Heart attacks 111

Heart attacks Heart Attack Peripheral Arterial Disease Ischemia 111

The American Journal of Cardiology

AUGUST 5, 2024

Publication date: Available online 5 August 2024 Source: The American Journal of Cardiology Author(s): Sameh Sayfo, Zachary P. Rosol, David Fernandez Vazquez, Mufaddal Mamawala, Blake M. Bruneman, Sarah G. Weideman, Kennedy S. Adelman, Minseob Jeong, Bala Ramanan, Shirling Tsai, Nicolas W. Shammas, Peter P. Monteleone, Aravinda Nanjundappa, Hung B.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Stents Stent Outcomes 40

DAIC

MARCH 20, 2024

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease 105

DAIC

JANUARY 9, 2024

"The roundtable provided a unique opportunity to identify knowledge gaps and discuss how IVUS can enhance our understanding and treatment of peripheral arterial and deep venous pathology." They also emphasized the need for further research and evidence to support the integration of IVUS into routine clinical practice.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Ultrasound Angioplasty Patient Care 105

DAIC

NOVEMBER 8, 2024

In the DA+DCB arm, there was a trend toward higher stent-free patency through 12 months (79.1% versus 68.1%, · P=0.09) and a significantly lower provisional stenting rate (9.5% in 11 RCTs) were also similar or better than meta-analysis rates for balloon angioplasty or DCB, with variations based on study design and artery level.3-6

Stents 52

Stents Stent Angioplasty Peripheral Arterial Disease 52

Dr. Anish Koka

JULY 23, 2023

Most have gotten used to egregiously bad coverage of current events that fills the pages of today’s New York Times, but even by their now very low standards a recent telling of a story about peripheral artery disease was very bad. Dr. Dormu also performed a mechanical atherectomy of all three tibial vessels. 4.1.2017.

Vascular Care 52

Vascular Care Outpatient Peripheral Arterial Disease Stents 52

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

Circulation

NOVEMBER 11, 2024

Background:Symptomatic peripheral artery disease (PAD) is prevalent and targeted therapies include optimal medical care (OMC), supervised exercise therapy (SET) and revascularization (ST). Although most PAD trials focus on objective outcomes, improvement in quality of life is important to the patient.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Quality of Life Exercise Stents 40

The British Journal of Cardiology

AUGUST 1, 2024

Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovascular disease (CVD), stroke, and peripheral artery disease.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Myocardial Infarction Plaque Cardiovascular Disease 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

This unique case highlights the diagnostic and therapeutic challenges of a patient with multiple vascular risk factors who suffered from strokes secondary to BHS.MethodsA 79‐year‐old man with a past medical history of peripheral artery disease, abdominal aortic aneurysm, myocardial infarction with drug eluding stents (on dual antiplatelet therapy (DAPT)), (..)

Stenosis 40

Stenosis Peripheral Arterial Disease Atherosclerosis Pacemaker 40

Dr. Anish Koka

MAY 16, 2023

years of age, P <0.001), cerebral or peripheral artery disease (6.2% Women also had more cardiovascular risk factors, including hypertension (66.6% versus 63.2%; P <0.001), hyperlipidemia (68.9% versus 66.3%; P =0.004), older age (62.4±7.9 years of age versus 59.0±8.4 versus 43.4%; P <0.001).

Chest Pain 52

Chest Pain Coronary Artery Disease Cancer Heart attacks 52